3 articles published in JoVE
The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury Jully Gogoi-Tiwari1, Julia Köhn-Gaone1, Corey Giles2, Dirk Schmidt-Arras3, Francis D. Gratte1,4, Caryn L. Elsegood1, Geoffrey W. McCaughan5,6,7, Grant A. Ramm8,9, John K. Olynyk10,11, Janina E.E. Tirnitz-Parker1,12 1School of Biomedical Sciences & Curtin Health Innovation Research Institute, Curtin University, 2School of Public Health & Curtin Health Innovation Research Institute, Curtin University, 3Institute of Biochemistry, Christian-Albrechts-University, 4School of Veterinary and Life Sciences, Murdoch University, 5Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, 6Royal Prince Alfred Hospital, 7A.W. Morrow Gastroenterology and Liver Centre, 8QIMR Berghofer Medical Research Institute, 9Faculty of Medicine and Biomedical Sciences, The University of Queensland, 10Fiona Stanley and Fremantle Hospitals, 11School of Medical and Health Sciences, Edith Cowan University, 12School of Medicine and Pharmacology, University of Western Australia Here we describe a common method to induce chronic liver injury in mice by feeding of a choline-deficient and ethionine-supplemented (CDE) diet. We demonstrate health monitoring, liver perfusion, isolation, and preservation. A time course of six weeks can inform about liver injury, pathohistology, fibrosis, inflammatory, and liver progenitor cell responses.
Murine Model of Wound Healing Louise Dunn1,2, Hamish C. G Prosser1,2, Joanne T. M. Tan1,2, Laura Z. Vanags1,2, Martin K. C. Ng1,2,3, Christina A. Bursill1,2 1The Heart Research Institute, 2Sydney Medical School, University of Sydney, 3Cardiology Department, Royal Prince Alfred Hospital A murine model of cutaneous wound healing that can be used to assess therapeutic compounds in physiological and pathophysiological settings.
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing Jerry Zhou1, Larissa Belov1, Michael J. Solomon2, Charles Chan3, Stephen J. Clarke4, Richard I. Christopherson1 1School of Molecular Bioscience, University of Sydney, 2Department of Surgery, Royal Prince Alfred Hospital, 3Department of Anatomical Pathology, Department of Anatomical Pathology, 4Department of Medicine, Concord Repatriation General Hospital We described a procedure for the disaggregation of colorectal cancer (CRC) to produce viable single cells, which are then captured on customized antibody microarrays recognizing surface antigens (DotScan CRC microarray). Sub-populations of cells bound to the microarray can be profiled by fluorescence multiplexing using monoclonal antibodies tagged with fluorescent dyes.